These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 31883514

  • 1. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
    Baandrup Kristiansen MN, Veidal SS, Christoffersen C, Feigh M, Vrang N, Roth JD, Erickson M, Adorini L, Jelsing J.
    BMC Gastroenterol; 2019 Dec 28; 19(1):228. PubMed ID: 31883514
    [Abstract] [Full Text] [Related]

  • 2. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 3. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis.
    Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M.
    World J Gastroenterol; 2018 Jan 14; 24(2):195-210. PubMed ID: 29375205
    [Abstract] [Full Text] [Related]

  • 4. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
    Roth JD, Veidal SS, Fensholdt LKD, Rigbolt KTG, Papazyan R, Nielsen JC, Feigh M, Vrang N, Young M, Jelsing J, Adorini L, Hansen HH.
    Sci Rep; 2019 Jun 21; 9(1):9046. PubMed ID: 31227742
    [Abstract] [Full Text] [Related]

  • 5. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.
    Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH.
    World J Gastroenterol; 2019 Sep 07; 25(33):4904-4920. PubMed ID: 31543682
    [Abstract] [Full Text] [Related]

  • 6. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, GOLDEN-505 Investigator Study Group.
    Gastroenterology; 2016 May 07; 150(5):1147-1159.e5. PubMed ID: 26874076
    [Abstract] [Full Text] [Related]

  • 7. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ, Parkes D, Feigh M, Suschak JJ, Harris MS.
    Sci Rep; 2022 Apr 23; 12(1):6666. PubMed ID: 35461369
    [Abstract] [Full Text] [Related]

  • 8. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
    Adorini L, Rigbolt K, Feigh M, Roth J, Erickson M.
    PLoS One; 2024 Apr 23; 19(4):e0300809. PubMed ID: 38662778
    [Abstract] [Full Text] [Related]

  • 9. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH, Gillum MP, Vrang N, Jelsing J, Hansen HH, Feigh M, Oró D.
    Am J Physiol Gastrointest Liver Physiol; 2023 May 01; 324(5):G378-G388. PubMed ID: 36852934
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An Obesogenic Dietary Mouse Model of Nonalcoholic Steatohepatitis.
    Zarrouki B, Boucher J.
    Methods Mol Biol; 2020 May 01; 2164():121-127. PubMed ID: 32607889
    [Abstract] [Full Text] [Related]

  • 15. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death.
    Briand F, Heymes C, Bonada L, Angles T, Charpentier J, Branchereau M, Brousseau E, Quinsat M, Fazilleau N, Burcelin R, Sulpice T.
    Clin Transl Sci; 2020 May 01; 13(3):529-538. PubMed ID: 31981449
    [Abstract] [Full Text] [Related]

  • 16. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
    Briand F, Maupoint J, Brousseau E, Breyner N, Bouchet M, Costard C, Leste-Lasserre T, Petitjean M, Chen L, Chabrat A, Richard V, Burcelin R, Dubroca C, Sulpice T.
    Metabolism; 2021 Apr 01; 117():154707. PubMed ID: 33444606
    [Abstract] [Full Text] [Related]

  • 17. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL.
    Expert Opin Investig Drugs; 2020 Feb 01; 29(2):117-123. PubMed ID: 31523999
    [Abstract] [Full Text] [Related]

  • 18. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ, Leeming DJ, Detlefsen S, Bruun MF, Hjuler ST, Henriksen K, Hein P, Karsdal MA, Brockbank S, Cruwys S.
    Biomed Pharmacother; 2019 Mar 01; 111():926-933. PubMed ID: 30841472
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
    van den Hoek AM, Verschuren L, Caspers MPM, Worms N, Menke AL, Princen HMG.
    Sci Rep; 2021 Mar 03; 11(1):5050. PubMed ID: 33658534
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.